Advanced therapy medicinal products – cell and gene therapies – offer tremendous hope for patients either by actually curing serious diseases or by alleviating suffering. However, gene therapies in particular come at a staggering cost to the healthcare system. Until now, US payers have absorbed and managed the cost of ultra-expensive therapies, but how long can they continue to do so?

ICON conducted in-depth interviews with a cross-section of US payers to:

• Understand how payers perceive the value of advanced therapies
• Assess their approach to determining coverage
• Identify solutions for the challenges they face specific to cell and gene therapies

Read the whitepaper for a summary of this primary research and our recommendations for the biopharmaceutical industry.